1.Treatment of Diffuse Planar Xanthoma of the Face after One Session of 1,444-nm Neodymium-Doped Yttrium Aluminium Garnet Laser.
Ji Min LEE ; Seung Hyun CHUN ; Byoung Joon SO ; Min Gun YOO ; Sun Yae KIM ; Il Hwan KIM
Annals of Dermatology 2015;27(6):769-770
No abstract available.
Xanthomatosis*
;
Yttrium*
3.Influence of compaction pressure and pre-sintering temperature on the machinability of zirconia ceramic.
Huil HUANG ; Jing LI ; Fuqiang ZHANG ; Jing SUN ; Lian GAO
West China Journal of Stomatology 2011;29(5):534-541
OBJECTIVEIn order to make certain the compaction pressure as well as pre-sintering temperature on the machinability of the zirconia ceramic.
METHODS3 mol nano-size 3 mol yttria partially stabilized zirconia (3Y-TZP) powder were compacted at different isostatic pressure and sintered at different temperature. The cylindrical surface was traversed using a hard metal tool. Surface and edge quality were checked visually using light stereo microscopy.
RESULTSPre-sintering temperature had the obviously influence on the machinability of 3Y-TZP. The cutting surface was smooth, and the integrality of edge was better when the pre-sintering temperature was chosen between 800 degrees C to 900 degrees C. Compaction pressure showed only a weak influence on machinability of 3Y-TZP blanks, but the higher compaction pressure result in the poor surface quality.
CONCLUSIONThe best machinability of pre-sintered zirconia body was found for 800-900 degrees C pre-sintering temperature, and 200-300 MPa compaction pressure.
Ceramics ; Temperature ; Yttrium ; Zirconium
4.Treatment with the Pinhole Technique Using Erbium-Doped Yttrium Aluminium Garnet Laser for a Cafe au Lait Macule and Carbon Dioxide Laser for Facial Telangiectasia.
Bo Young CHUNG ; Seung Seog HAN ; Hye Rim MOON ; Mi Woo LEE ; Sung Eun CHANG
Annals of Dermatology 2014;26(5):657-659
No abstract available.
Lasers, Gas*
;
Telangiectasis*
;
Yttrium*
5.Effective Treatment of Congenital Melanocytic Nevus and Nevus Sebaceous Using the Pinhole Method with the Erbium-Doped Yttrium Aluminium Garnet Laser.
Bo Young CHUNG ; Seung Seog HAN ; Byung Wook KIM ; Sung Eun CHANG ; Mi Woo LEE
Annals of Dermatology 2014;26(5):651-653
No abstract available.
Nevus*
;
Nevus, Pigmented*
;
Yttrium*
6.Erbium-doped Yttrium Aluminum Garnet Laser to Treat Familial Acanthosis Nigricans.
Won Seon KOH ; Hyung Kwon PARK ; Ho Song KANG ; Joung Soo KIM
Korean Journal of Dermatology 2018;56(10):649-651
No abstract available.
Acanthosis Nigricans*
;
Aluminum*
;
Yttrium*
7.Clinical Factors Influencing Outcomes of 1064 nm Neodymium-Doped Yttrium Aluminum Garnet (Nd:YAG) Laser Treatment for Onychomycosis.
Hyun Joo KIM ; Hyung jin PARK ; Dong Hye SUH ; Sang Jun LEE ; Ki Heon JEONG ; Mu Hyoung LEE ; Min Kyung SHIN
Annals of Dermatology 2018;30(4):493-495
No abstract available.
Aluminum*
;
Onychomycosis*
;
Yttrium*
8.A Prospective Split-Face Comparative Study of Periorbital Wrinkle Treatments: Fractional Erbium-Doped Yttrium Aluminum Garnet Laser, Intense Pulsed Light, and Topical 0.1% Tretinoin Cream.
So Eun PARK ; Sang Seok KIM ; Chul Woo KIM ; Young HER
Annals of Dermatology 2016;28(5):650-652
No abstract available.
Aluminum*
;
Prospective Studies*
;
Tretinoin*
;
Yttrium*
9.A Prospective Split-Face Comparative Study of Periorbital Wrinkle Treatments: Fractional Erbium-Doped Yttrium Aluminum Garnet Laser, Intense Pulsed Light, and Topical 0.1% Tretinoin Cream.
So Eun PARK ; Sang Seok KIM ; Chul Woo KIM ; Young HER
Annals of Dermatology 2016;28(5):650-652
No abstract available.
Aluminum*
;
Prospective Studies*
;
Tretinoin*
;
Yttrium*
10.Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
Edward Wolfgang LEE ; Sarah KHAN
Clinical and Molecular Hepatology 2017;23(4):265-272
Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (⁹⁰Y) have played an increasingly important role for these patients with unresectable HCC. With a better understanding of different transarterial embolotherapies, more personalized and precise treatment should be implemented for these patients with unresectable HCC. In this review, the updated evidence on the current role of each embolotherapy in the treatment of HCC is summarized.
Carcinoma, Hepatocellular*
;
Embolization, Therapeutic*
;
Humans
;
Yttrium
Result Analysis
Print
Save
E-mail